Report: Indian Drug Makers Too Risk-Averse
This article was originally published in PharmAsia News
PricewaterhouseCoopers, the U.S. accounting/consulting firm, says in a new report that Indian drug makers are not taking the risks they should for creating new treatments. The report cited a basic conflict between drug makers and governments over the price of drugs. The report noted pharmaceutical companies often are flying blind when they attempt to develop a new drug. The report urged governments to adopt policies that spur innovative research, and back that work with good intellectual-property laws. (Click here for more
You may also be interested in...
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.